Notably, IL-23 signaling and Th1/Th17 immunity are important mechanisms of intestinal inflammation, and thus IL-1α/IL-1β, the upstream of IL-23 inhibition, can be targeted to treat IBD (41). The gene discussed is IL1A; the disease is inflammatory bowel disease.